Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07088419 · ClinicalTrials.gov registry record · Phase 2
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
A Phase 2 study of Mycoplasma Genitalium and Non-gonococcal Urethritis (NGU), sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07088419 is a Phase 2 study of Mycoplasma Genitalium and Non-gonococcal Urethritis (NGU) that is actively recruiting participants, run by University of Washington. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07088419, a Phase 2 study of Mycoplasma Genitalium and Non-gonococcal Urethritis (NGU), is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective is to estimate the efficacy of tinidazole for the treatment of Mycoplasma genitalium (MG) among male patients who have been diagnosed with non-gonococcal urethritis (NGU) at the Public Health - Seattle \&King County (PHSKC) Sexual Health Clinic (SHC). Tinidazole was approved by the Food and Drug Administration (FDA) in May 2004 to treat other infections (i.e., trichomoniasis, giardiasis, amebiasis, bacterial vaginosis) but has not been systematically tested for effectiveness against M. genitalium. The dosing that the investigators are proposing does not significantly increase the risk associated with taking tinidazole and this investigation meets criteria for an IND exemption.
Conditions Studied
Interventions
- DRUG Tinidazole
Study Locations (1)
Washington
- Harborview Medical Center, Public Health - Seattle & King County Sexual Health Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07088419
The ClinicalTrials.gov registry entry for NCT07088419 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mycoplasma Genitalium appearing as the primary indexed condition, and to 1 intervention - of which Tinidazole is the first listed.
NCT07088419 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT07088419 about?
NCT07088419 is a clinical study titled ""Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"". The objective is to estimate the efficacy of tinidazole for the treatment of Mycoplasma genitalium (MG) among male patients who have been diagnosed with non-gonococcal urethritis (NGU) at the Public Health - Seattle \&King County (PHSKC) Sexual Health Clinic (SHC). Tinidazole was approved by the Foo...
What is the current status of trial NCT07088419?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-07-23. Estimated completion is 2026-08-31.
What conditions does trial NCT07088419 study?
This clinical trial studies the following conditions: Mycoplasma Genitalium, Non-gonococcal Urethritis (NGU).
What interventions are being tested in trial NCT07088419?
The interventions under investigation include: Tinidazole (DRUG).
Who is sponsoring clinical trial NCT07088419?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07088419 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.